

Mark D Stegall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1991839/publications.pdf>

Version: 2024-02-01

277
papers

15,629
citations

14614

66
h-index

21474

114
g-index

284
all docs

284
docs citations

284
times ranked

12875
citing authors

#	ARTICLE	IF	CITATIONS
1	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATION—A MULTIVARIATE ANALYSIS. <i>Transplantation</i> , 1993, 55, 807-813.	0.5	937
2	Structural and Functional Changes With the Aging Kidney. <i>Advances in Chronic Kidney Disease</i> , 2016, 23, 19-28.	0.6	476
3	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	2.6	437
4	The Association Between Age and Nephrosclerosis on Renal Biopsy Among Healthy Adults. <i>Annals of Internal Medicine</i> , 2010, 152, 561.	2.0	391
5	Measured and estimated GFR in healthy potential kidney donors. <i>American Journal of Kidney Diseases</i> , 2004, 43, 112-119.	2.1	348
6	New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. <i>Kidney International</i> , 2005, 67, 2415-2421.	2.6	337
7	WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS ¹ . <i>Transplantation</i> , 2004, 77, 1555-1561.	0.5	284
8	Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance Biopsies. <i>American Journal of Transplantation</i> , 2005, 5, 2464-2472.	2.6	279
9	Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. <i>New England Journal of Medicine</i> , 2016, 374, 940-950.	13.9	279
10	The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 313-320.	3.0	272
11	RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION ^{1, 2} . <i>Transplantation</i> , 2000, 69, 834-841.	0.5	270
12	Single-Nephron Glomerular Filtration Rate in Healthy Adults. <i>New England Journal of Medicine</i> , 2017, 376, 2349-2357.	13.9	247
13	The relevance of animal models in multiple sclerosis research. <i>Pathophysiology</i> , 2011, 18, 21-29.	1.0	244
14	Overcoming a Positive Crossmatch in Living-Donor Kidney Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 1017-1023.	2.6	239
15	Deep Learning–Based Histopathologic Assessment of Kidney Tissue. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1968-1979.	3.0	226
16	The role of complement in antibody-mediated rejection in kidney transplantation. <i>Nature Reviews Nephrology</i> , 2012, 8, 670-678.	4.1	204
17	Fibrosis with Inflammation at One Year Predicts Transplant Functional Decline. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1987-1997.	3.0	194
18	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4923.	2.4	191

#	ARTICLE	IF	CITATIONS
19	ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. <i>Transplantation</i> , 2003, 75, 971-977.	0.5	187
20	Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2005, 23, 7574-7582.	0.8	182
21	Accommodation in ABO-Incompatible Kidney Allografts, a Novel Mechanism of Self-Protection Against Antibody-Mediated Injury. <i>American Journal of Transplantation</i> , 2003, 3, 952-960.	2.6	177
22	Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis: Outcomes and Response to Therapy for Recurrence. <i>Transplantation</i> , 2009, 87, 1232-1239.	0.5	173
23	Improved Scoring System to Assess Adult Donors For Cadaver Renal Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 715-721.	2.6	170
24	Transplant Glomerulopathy: Risk and Prognosis Related to Anti-Human Leukocyte Antigen Class II Antibody Levels. <i>Transplantation</i> , 2008, 86, 681-685.	0.5	168
25	Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. <i>Kidney International</i> , 2003, 64, 665-673.	2.6	157
26	Obesity in Living Kidney Donors: Clinical Characteristics and Outcomes in the Era of Laparoscopic Donor Nephrectomy. <i>American Journal of Transplantation</i> , 2005, 5, 1057-1064.	2.6	150
27	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. <i>Transplantation</i> , 2004, 78, 276-282.	0.5	142
28	Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases?. <i>Transplantation</i> , 2005, 79, 244-247.	0.5	140
29	Chronic renal dysfunction late after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 916-921.	1.3	134
30	PREDNISONE WITHDRAWAL 14 DAYS AFTER LIVER TRANSPLANTATION WITH MYCOPHENOLATE. <i>Transplantation</i> , 1997, 64, 1755-1760.	0.5	129
31	Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. <i>Transplantation</i> , 2003, 75, 2048-2053.	0.5	128
32	RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS ¹ . <i>Transplantation</i> , 2001, 72, 245-250.	0.5	126
33	ABO-Incompatible Kidney Transplantation. <i>Transplantation</i> , 2004, 78, 635-640.	0.5	119
34	Kidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1130-1136.	2.6	118
35	Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation. <i>Transplantation</i> , 2008, 86, 1384-1388.	0.5	114
36	Through a Glass Darkly. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 20-29.	3.0	112

#	ARTICLE	IF	CITATIONS
37	RETRANSPLANTATION OF THE LIVER—A SEVEN-YEAR EXPERIENCE. <i>Transplantation</i> , 1993, 55, 1083-1086.	0.5	110
38	EVIDENCE OF RECURRENT AUTOIMMUNITY IN HUMAN ALLOGENEIC ISLET TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 1272-1274.	0.5	109
39	Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 8-10.	0.8	104
40	Pancreas transplantation. <i>BMJ: British Medical Journal</i> , 2017, 357, j1321.	2.4	102
41	Subclinical Rejection in Tacrolimus-Treated Renal Transplant Recipients. <i>Transplantation</i> , 2002, 73, 1965-1967.	0.5	101
42	Histologic Findings of Antibody-Mediated Rejection in ABO Blood-Group-Incompatible Living-Donor Kidney Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 101-107.	2.6	96
43	Persistence of Low Levels of Alloantibody after Desensitization in Crossmatch-Positive Living-Donor Kidney Transplantation. <i>Transplantation</i> , 2004, 78, 221-227.	0.5	95
44	A Comparison of Splenectomy versus Intensive Posttransplant Antidonator Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation. <i>Transplantation</i> , 2005, 80, 1572-1577.	0.5	95
45	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. <i>American Journal of Transplantation</i> , 2019, 19, 2876-2888.	2.6	95
46	Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 2034-2039.	0.4	90
47	Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys. <i>Transplantation</i> , 2017, 101, 867-872.	0.5	90
48	Improving the Prediction of Donor Kidney Quality: Deceased Donor Score and Resistive Indices. <i>Transplantation</i> , 2005, 80, 925-929.	0.5	89
49	Prevalence of Renal Artery and Kidney Abnormalities by Computed Tomography among Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 431-438.	2.2	89
50	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2032-2036.	0.4	88
51	Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates. <i>Transplantation</i> , 2013, 96, 394-399.	0.5	88
52	Sensitized renal transplant recipients: current protocols and future directions. <i>Nature Reviews Nephrology</i> , 2010, 6, 297-306.	4.1	86
53	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1206-1219.	3.0	85
54	MYCOPHENOLATE MOFETIL DECREASES REJECTION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION WHEN COMBINED WITH TACROLIMUS OR CYCLOSPORINE. <i>Transplantation</i> , 1997, 64, 1695-1700.	0.5	85

#	ARTICLE	IF	CITATIONS
55	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. <i>American Journal of Transplantation</i> , 2005, 5, 1660-1670.	2.6	83
56	Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. <i>Kidney International</i> , 2016, 89, 909-917.	2.6	83
57	Donor Scoring System for Cadaveric Renal Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 162-170.	2.6	82
58	Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies. <i>Transplantation</i> , 2007, 83, 411-416.	0.5	81
59	Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy. <i>American Journal of Transplantation</i> , 2004, 4, 248-256.	2.6	79
60	Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. <i>American Journal of Kidney Diseases</i> , 2016, 68, 58-67.	2.1	78
61	MRI in Rodent Models of Brain Disorders. <i>Neurotherapeutics</i> , 2011, 8, 3-18.	2.1	76
62	CD8 ⁺ T cells in multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1053-1066.	1.5	76
63	Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. <i>Journal of Biological Chemistry</i> , 2015, 290, 30697-30712.	1.6	76
64	Prospective, randomized evaluation of a cuffed expanded polytetrafluoroethylene graft for hemodialysis vascular access. <i>Surgery</i> , 2002, 132, 135-140.	1.0	72
65	Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR. <i>Kidney International</i> , 2004, 66, 1654-1661.	2.6	72
66	PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS ¹ . <i>Transplantation</i> , 2004, 77, 1269-1275.	0.5	70
67	Reassessing Preemptive Kidney Transplantation in the United States. <i>Transplantation</i> , 2016, 100, 1120-1127.	0.5	70
68	The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In Vivo. <i>Transplantation</i> , 2011, 91, 536-541.	0.5	68
69	The Rationale for the New Deceased Donor Pancreas Allocation Schema. <i>Transplantation</i> , 2007, 83, 1156-1161.	0.5	67
70	32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. <i>Transplantation</i> , 2017, 101, 1222-1227.	0.5	67
71	Pancreas Transplants: Experience with 232 Percutaneous US-guided Biopsy Procedures in 88 Patients. <i>Radiology</i> , 2004, 231, 845-849.	3.6	66
72	Antibody-mediated rejection following transplantation from an HLA-identical sibling. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 307-310.	0.4	66

#	ARTICLE	IF	CITATIONS
73	Antibody-mediated rejection in liver transplantation: Current controversies and future directions. <i>Liver Transplantation</i> , 2014, 20, 514-527.	1.3	62
74	Diurnal Blood Pressure Changes One Year after Kidney Transplantation: Relationship to Allograft Function, Histology, and Resistive Index. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1607-1615.	3.0	60
75	Preemptive Living Donor Kidney Transplantation: Do the Benefits Extend to All Recipients?. <i>Transplantation</i> , 2007, 83, 144-149.	0.5	59
76	Association of Kidney Function and Metabolic Risk Factors With Density of Glomeruli on Renal Biopsy Samples From Living Donors. <i>Mayo Clinic Proceedings</i> , 2011, 86, 282-290.	1.4	59
77	IMPROVED RESULTS USING OKT3 AS INDUCTION IMMUNOSUPPRESSION IN RENAL ALLOGRAFT RECIPIENTS WITH DELAYED GRAFT FUNCTION. <i>Transplantation</i> , 1990, 49, 321-326.	0.5	58
78	Apoptosis of Hippocampal Pyramidal Neurons Is Virus Independent in a Mouse Model of Acute Neurovirulent Picornavirus Infection. <i>American Journal of Pathology</i> , 2009, 175, 668-684.	1.9	58
79	Antibody-mediated rejection despite inhibition of terminal complement. <i>Transplant International</i> , 2014, 27, 1235-1243.	0.8	58
80	Blood Pressure Evaluation among Older Living Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2159-2167.	3.0	57
81	Complications, Resource Utilization, and Cost of ABO-Incompatible Living Donor Kidney Transplantation. <i>Transplantation</i> , 2006, 82, 155-163.	0.5	57
82	Long-term benefits of pancreas transplantation. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 85-90.	0.8	55
83	Specific renal parenchymal-derived urinary extracellular vesicles identify age-associated structural changes in living donor kidneys. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 29642.	5.5	55
84	Free Fatty Acid Storage in Human Visceral and Subcutaneous Adipose Tissue. <i>Diabetes</i> , 2011, 60, 2300-2307.	0.3	53
85	Prospective, Randomized, Multi-Center Trial of Antibody Induction Therapy in Simultaneous Pancreas-Kidney Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 855-864.	2.6	52
86	Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2607-2614.	0.4	52
87	Interpreting Anti-HLA Antibody Testing Data. <i>Transplantation</i> , 2016, 100, 1619-1628.	0.5	52
88	Why do we have the kidney allocation system we have today? A history of the 2014 kidney allocation system. <i>Human Immunology</i> , 2017, 78, 4-8.	1.2	50
89	Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch. <i>Transplantation</i> , 2017, 101, 2429-2439.	0.5	49
90	Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases. <i>Transplantation</i> , 2019, 103, 2397-2404.	0.5	49

#	ARTICLE	IF	CITATIONS
91	Acute Nephrotoxicity of Tacrolimus and Sirolimus in Renal Isografts: Differential Intragraft Expression of Transforming Growth Factor- β 1 and α -Smooth Muscle Actin. <i>Transplantation</i> , 2004, 78, 338-344.	0.5	48
92	Unique molecular changes in kidney allografts after simultaneous liver-kidney compared with solitary kidney transplantation. <i>Kidney International</i> , 2017, 91, 1193-1202.	2.6	48
93	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. <i>Clinical Transplantation</i> , 2019, 33, e13751.	0.8	48
94	Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. <i>American Journal of Transplantation</i> , 2019, 19, 1671-1683.	2.6	48
95	Gene Expression During Acute Allograft Rejection: Novel Statistical Analysis of Microarray Data. <i>American Journal of Transplantation</i> , 2002, 2, 913-925.	2.6	46
96	United Network for Organ Sharing's expanded criteria donors: is stratification useful?*. <i>Clinical Transplantation</i> , 2005, 19, 406-412.	0.8	44
97	Early Subclinical Coronary Artery Calcification in Young Adults Who Were Pediatric Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1689-1693.	2.6	43
98	Significance and Implications of Capillaritis During Acute Rejection of Kidney Allografts. <i>Transplantation</i> , 2010, 89, 1088-1094.	0.5	43
99	Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year. <i>Kidney International</i> , 2018, 93, 1465-1474.	2.6	41
100	Implication of TIGIT+ human memory B cells in immune regulation. <i>Nature Communications</i> , 2021, 12, 1534.	5.8	41
101	Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2561-2575.	1.4	41
102	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
103	Intravitreal Antivasular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts. <i>Transplantation</i> , 2015, 99, 2382-2386.	0.5	39
104	Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 476-482.	2.2	39
105	Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1471-1480.	3.0	39
106	Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. <i>American Journal of Transplantation</i> , 2019, 19, 1989-1998.	2.6	39
107	ABO incompatible kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 529-534.	1.0	38
108	Epidemiology of Infections Requiring Hospitalization During Long-Term Follow-Up of Pancreas Transplantation. <i>Transplantation</i> , 2010, 89, 1126-1133.	0.5	38

#	ARTICLE	IF	CITATIONS
109	A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 831-42.	1.2	38
110	Decline in native renal function early after bladder-drained pancreas transplantation alone. <i>Transplantation</i> , 2004, 77, 844-849.	0.5	37
111	A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds. <i>BMC Genomics</i> , 2007, 8, 88.	1.2	37
112	The (re)emergence of B cells in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 451-455.	0.8	37
113	Pancreas-after-kidney transplantation: an increasingly attractive alternative to simultaneous pancreas-kidney transplantation. <i>Transplantation</i> , 2004, 77, 838-843.	0.5	36
114	Molecular Evidence of Injury and Inflammation in Normal and Fibrotic Renal Allografts One Year Posttransplant. <i>Transplantation</i> , 2007, 83, 1466-1476.	0.5	36
115	Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3165-3174.	3.0	35
116	De novo donor-specific antibody following BK nephropathy: The incidence and association with antibody-mediated rejection. <i>Clinical Transplantation</i> , 2018, 32, e13194.	0.8	35
117	Islet and Pancreatic Transplantation " Autoimmunity and Alloimmunity. <i>New England Journal of Medicine</i> , 1996, 335, 888-890.	13.9	34
118	Can a Transplanted Living Donor Kidney Function Equivalently to its Native Partner?. <i>American Journal of Transplantation</i> , 2002, 2, 252-259.	2.6	33
119	Compensatory Hypertrophy of the Remaining Kidney in Medically Complex Living Kidney Donors Over the Long Term. <i>Transplantation</i> , 2015, 99, 555-559.	0.5	33
120	Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1960-1969.	3.0	33
121	The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2020, 6, e524.	0.8	33
122	PANCREATIC ISLET TRANSPLANTATION IN CYNOMOLGUS MONKEYS. <i>Transplantation</i> , 1989, 48, 944-950.	0.5	32
123	Identification and Characterization of Kidney Transplants With Good Glomerular Filtration Rate at 1 Year But Subsequent Progressive Loss of Renal Function. <i>Transplantation</i> , 2012, 94, 931-939.	0.5	32
124	Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2012, 35, 365-371.	1.4	32
125	Survival of mandatorily shared cadaveric kidneys and their paybacks in the zero mismatch era. <i>Transplantation</i> , 2002, 74, 670-675.	0.5	31
126	Relationship between pre-transplant physical function and outcomes after kidney transplant. <i>Clinical Transplantation</i> , 2017, 31, e12952.	0.8	31

#	ARTICLE	IF	CITATIONS
127	Living Donor Kidney Transplantation Using Laparoscopically Procured Multiple Renal Artery Kidneys and Right Kidneys. <i>Journal of the American College of Surgeons</i> , 2013, 217, 144-152.	0.2	30
128	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2642-2652.	3.0	30
129	Polyclonal and Monoclonal Antibodies in Clinic. <i>Methods in Molecular Biology</i> , 2014, 1060, 79-110.	0.4	30
130	INTERSTITIAL CLASS II-POSITIVE CELL DEPLETION BY DONOR PRETREATMENT WITH GAMMA IRRADIATION. <i>Transplantation</i> , 1990, 49, 246-250.	0.5	29
131	Kidney Structural Features from Living Donors Predict Graft Failure in the Recipient. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 415-423.	3.0	29
132	The Effect of Antithymocyte Globulin on Anti-“Human Leukocyte Antigen Antibody Detection Assays. <i>Transplantation</i> , 2007, 84, 258-264.	0.5	28
133	The Relationship Between Frailty and Decreased Physical Performance With Death on the Kidney Transplant Waiting List. <i>Progress in Transplantation</i> , 2019, 29, 108-114.	0.4	27
134	HUMORAL IMMUNITY IN ALLOGRAFT REJECTION. <i>Transplantation</i> , 1989, 48, 751-755.	0.5	26
135	Changes in intragraft gene expression secondary to ischemia reperfusion after cardiac transplantation. <i>Transplantation</i> , 2002, 74, 924-930.	0.5	26
136	Kidney Transplant Histology After One Year of Continuous Therapy With Sirolimus Compared With Tacrolimus. <i>Transplantation</i> , 2008, 85, 1212-1215.	0.5	26
137	The conundrums of chronic kidney disease and aging. <i>Journal of Nephrology</i> , 2017, 30, 477-483.	0.9	26
138	Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis. <i>Neurology Research International</i> , 2011, 2011, 1-14.	0.5	25
139	AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-“Th17 Axis. <i>Journal of Immunology</i> , 2016, 197, 747-760.	0.4	25
140	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	5.9	25
141	Tumor Necrosis Factor $\hat{\pm}$ is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virus-Induced Encephalitis. <i>Brain Pathology</i> , 2009, 19, 12-26.	2.1	24
142	A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study. <i>Transplant International</i> , 2019, 32, 173-183.	0.8	24
143	Kidney Microstructural Features at the Time of Donation Predict Long-term Risk of Chronic Kidney Disease in Living Kidney Donors. <i>Mayo Clinic Proceedings</i> , 2021, 96, 40-51.	1.4	24
144	Patient experience after kidney transplant: a conceptual framework of treatment burden. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 8.	0.9	23

#	ARTICLE	IF	CITATIONS
145	THYMOGLOBULIN INDUCTION DECREASES REJECTION IN SOLITARY PANCREAS TRANSPLANTATION. <i>Transplantation</i> , 2001, 72, 1671-1675.	0.5	23
146	Preliminary Experience with a Cuffed ePTFE Graft for Hemodialysis Vascular Access. <i>ASAIO Journal</i> , 2001, 47, 333-337.	0.9	22
147	Abnormal circadian blood pressure pattern 1-year after kidney transplantation is associated with subsequent lower glomerular filtration rate in recipients without rejection. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 39-47.	2.3	22
148	New insights regarding chronic antibody-mediated rejection and its progression to transplant glomerulopathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 611-618.	1.0	22
149	Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 449-463.	1.4	22
150	Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice. <i>Nucleic Acid Therapeutics</i> , 2015, 25, 11-19.	2.0	22
151	Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease. <i>Molecular Neurobiology</i> , 2016, 53, 5217-5228.	1.9	22
152	Assessing the Efficacy of Kidney Paired Donationâ€”Performance of an Integrated Three-Site Program. <i>Transplantation</i> , 2014, 98, 300-305.	0.5	21
153	Effects of Aspirin Therapy on Ultrasoundâ€”Guided Renal Allograft Biopsy Bleeding Complications. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 188-194.	0.2	21
154	A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2623-2633.	3.0	21
155	Brainstem ¹ H nuclear magnetic resonance (NMR) spectroscopy: Marker of demyelination and repair in spinal cord. <i>Annals of Neurology</i> , 2009, 66, 559-564.	2.8	20
156	A Single Dose of Neuron-Binding Human Monoclonal Antibody Improves Spontaneous Activity in a Murine Model of Demyelination. <i>PLoS ONE</i> , 2011, 6, e26001.	1.1	20
157	Preclinical ¹ H-MRS neurochemical profiling in neurological and psychiatric disorders. <i>Bioanalysis</i> , 2012, 4, 1787-1804.	0.6	20
158	Differences in Chronic Intragraft Inflammation Between Positive Crossmatch and ABO-Incompatible Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 1089-1096.	0.5	20
159	Outcome of Untreated Grade II Rejection on Solitary Pancreas Allograft Biopsy Specimens. <i>Transplantation</i> , 2005, 79, 1717-1722.	0.5	19
160	Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs. <i>Transplantation</i> , 2020, 104, 1229-1238.	0.5	19
161	??4 INTEGRIN IN ISLET ALLOGRAFT REJECTION1. <i>Transplantation</i> , 2001, 71, 1549-1555.	0.5	18
162	Forskolin suppresses insulin gene transcription in islet β -cells through a protein kinase A-independent pathway. <i>Cellular Signalling</i> , 2003, 15, 27-35.	1.7	18

#	ARTICLE	IF	CITATIONS
163	Conquering absolute contraindications to transplantation: Positive-crossmatch and ABO-incompatible kidney transplantation. <i>Surgery</i> , 2005, 137, 269-273.	1.0	18
164	In-vivo techniques for determining nephron number. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 545-551.	1.0	18
165	Abbreviated Exposure to Hypoxia Is Sufficient to Induce CNS Dysmyelination, Modulate Spinal Motor Neuron Composition, and Impair Motor Development in Neonatal Mice. <i>PLoS ONE</i> , 2015, 10, e0128007.	1.1	18
166	Autoimmune Destruction of Islet Grafts in the NOD Mouse Is Resistant to 15-Deoxyspergualin but Sensitive to Anti-CD4 Antibody. <i>Journal of Surgical Research</i> , 1996, 64, 156-160.	0.8	17
167	Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients. <i>Depression and Anxiety</i> , 2011, 28, 1111-1118.	2.0	17
168	The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. <i>American Journal of Transplantation</i> , 2019, 19, 625-632.	2.6	17
169	Down-Regulating Humoral Immune Responses. <i>Transplantation</i> , 2014, 97, 247-257.	0.5	16
170	Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases. <i>JAMA Neurology</i> , 2015, 72, 1346.	4.5	16
171	Identifying Barriers to Preemptive Kidney Transplantation in a Living Donor Transplant Cohort. <i>Transplantation Direct</i> , 2018, 4, e356.	0.8	16
172	Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study. <i>Transplant International</i> , 2019, 32, 502-515.	0.8	16
173	Convolutional Neural Networks for the Evaluation of Chronic and Inflammatory Lesions in Kidney Transplant Biopsies. <i>American Journal of Pathology</i> , 2022, 192, 1418-1432.	1.9	16
174	The Development of Kidney Allocation Policy. <i>American Journal of Kidney Diseases</i> , 2005, 46, 974-975.	2.1	15
175	ABO-Incompatible Kidney Transplantation with and without Splenectomy. <i>Transplantation</i> , 2006, 82, 720.	0.5	15
176	Transgenic Expression of the 3D Polymerase Inhibits Theiler's Virus Infection and Demyelination. <i>Journal of Virology</i> , 2009, 83, 12279-12289.	1.5	15
177	Using Implantation Biopsies as a Surrogate to Evaluate Selection Criteria for Living Kidney Donors. <i>Transplantation</i> , 2013, 96, 975-980.	0.5	15
178	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	2.1	15
179	The Kidney in Normal Aging. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 137-139.	2.2	15
180	Cyclosporine elimination in the presence of TOR inhibitors: Effects on renal function, acute rejection, and safety. <i>American Journal of Kidney Diseases</i> , 2001, 38, S3-S10.	2.1	14

#	ARTICLE	IF	CITATIONS
181	Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. <i>Current Transplantation Reports</i> , 2014, 1, 78-85.	0.9	14
182	Adherence to a pedometerâ€based physical activity intervention following kidney transplant and impact on metabolic parameters. <i>Clinical Transplantation</i> , 2015, 29, 560-568.	0.8	14
183	Single-Nephron Glomerular Filtration Rate in Healthy Adults. <i>New England Journal of Medicine</i> , 2017, 377, 1202-1204.	13.9	14
184	Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1017-1026.	0.4	14
185	Current Approaches to Desensitization in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 686271.	2.2	14
186	ABO-incompatible liver transplant: Is it justifiable?. <i>Liver Transplantation</i> , 2003, 9, 31.	1.3	13
187	Decreased Incidence of Acute Rejection in Adolescent Kidney Transplant Recipients Using Antithymocyte Induction and Triple Immunosuppression. <i>Transplantation</i> , 2007, 84, 715-721.	0.5	13
188	Deletion of Betaâ€2â€Microglobulin Ameliorates Spinal Cord Lesion Load and Promotes Recovery of Brainstem NAA Levels in a Murine Model of Multiple Sclerosis. <i>Brain Pathology</i> , 2012, 22, 698-708.	2.1	13
189	Using computer-assisted morphometrics of 5-year biopsies to identify biomarkers of late renal allograft loss. <i>American Journal of Transplantation</i> , 2019, 19, 2846-2854.	2.6	13
190	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.	2.6	13
191	Automated Segmentation of Kidney Cortex and Medulla in CT Images: A Multisite Evaluation Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 420-430.	3.0	13
192	Inter and intra laboratory concordance of HLA antibody results obtained by single antigen bead based assay. <i>Human Immunology</i> , 2013, 74, 310-317.	1.2	12
193	Obesity-Related Glomerulopathy and Single-Nephron GFR. <i>Kidney International Reports</i> , 2020, 5, 1126-1128.	0.4	12
194	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. <i>American Journal of Transplantation</i> , 2021, 21, 1278-1284.	2.6	12
195	Pancreas Transplantation for the Prevention of Diabetic Nephropathy. <i>Mayo Clinic Proceedings</i> , 2000, 75, 49-56.	1.4	11
196	Transgenic Expression of Viral Capsid Proteins Predisposes to Axonal Injury in a Murine Model of Multiple Sclerosis. <i>Brain Pathology</i> , 2011, 21, no-no.	2.1	11
197	The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. <i>Transplant Immunology</i> , 2012, 27, 95-100.	0.6	11
198	The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 535-549.	1.3	11

#	ARTICLE	IF	CITATIONS
199	Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study. <i>American Journal of Transplantation</i> , 2018, 18, 650-658.	2.6	11
200	Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13719.	0.8	11
201	The need for novel trial designs, master protocols, and research consortia in transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13759.	0.8	11
202	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1612-1621.	2.6	11
203	Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14718.	0.8	11
204	Hand-assisted laparoscopic donor nephrectomy for pediatric kidney allograft recipients. <i>Pediatric Transplantation</i> , 2004, 8, 460-463.	0.5	10
205	The Right Kidney for the Right Recipient: The Status of Deceased Donor Kidney Allocation Reform. <i>Seminars in Dialysis</i> , 2010, 23, 248-252.	0.7	10
206	Obesity Correlates With Glomerulomegaly But Is Not Associated With Kidney Dysfunction Early After Donation. <i>Transplantation Direct</i> , 2015, 1, 1-6.	0.8	10
207	A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 83.	3.1	10
208	A monoclonal natural human IgM protects axons in the absence of remyelination. <i>Journal of Neuroinflammation</i> , 2016, 13, 94.	3.1	10
209	Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. <i>American Journal of Nephrology</i> , 2016, 43, 454-459.	1.4	10
210	Preoperative Factors Predicting Admission to the Intensive Care Unit After Kidney Transplantation. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 285-293.	1.2	9
211	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. <i>Liver Transplantation</i> , 2020, 26, 549-563.	1.3	9
212	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. <i>American Journal of Kidney Diseases</i> , 2022, 79, 202-216.	2.1	9
213	Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management. <i>Transplantation Direct</i> , 2022, 8, e1273.	0.8	9
214	Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. <i>Journal of Autoimmunity</i> , 2004, 23, 201-209.	3.0	8
215	Need for a paradigm shift in therapeutic approaches to CNS injury. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 409-420.	1.4	8
216	Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis. <i>Journal of Clinical Immunology</i> , 2013, 33, 50-56.	2.0	8

#	ARTICLE	IF	CITATIONS
217	Kidney donors at increased risk? Additional studies are needed. <i>Kidney International</i> , 2014, 86, 650.	2.6	8
218	Global Glomerulosclerosis in Kidney Biopsies With Differing Amounts of Cortex: A Clinical-Pathologic Correlation Study. <i>Kidney Medicine</i> , 2019, 1, 153-161.	1.0	8
219	Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. <i>Human Antibodies</i> , 2017, 25, 121-129.	0.6	7
220	The effect of coronary angiography on renal function in preemptive renal transplant candidates. <i>Clinical Transplantation</i> , 2011, 25, 594-599.	0.8	6
221	Renal retransplantation after kidney and pancreas transplantation using the renal vessels of the failed allograft: pitfalls and pearls. <i>Clinical Transplantation</i> , 2014, 28, 669-674.	0.8	6
222	Early subclinical inflammation correlates with outcomes in positive crossmatch kidney allografts. <i>Clinical Transplantation</i> , 2016, 30, 925-933.	0.8	6
223	Minimal effect of bortezomib in reducing anti- ϵ pig antibodies in human leukocyte antigen-sensitized patients: a pilot study. <i>Xenotransplantation</i> , 2013, 20, 429-437.	1.6	5
224	Genes and Transplant Outcomes. <i>Transplantation</i> , 2014, 98, 257-258.	0.5	5
225	Obesity and Metabolic Syndrome in Kidney Transplantation: The Role of Dietary Fructose and Systemic Endotoxemia. <i>Transplantation</i> , 2019, 103, 191-201.	0.5	5
226	Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis. , 2014, 2, .		5
227	Healthy and unhealthy aging on kidney structure and function. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, Publish Ahead of Print, .	1.0	5
228	Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study. <i>Kidney360</i> , 2022, 3, 1411-1416.	0.9	5
229	Renal ablation using bilateral ureteral ligation for nephrotic syndrome due to renal amyloidosis. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 153-154.	1.4	4
230	Renal function outcomes and kidney biopsy features of living kidney donors with hypertension. <i>Clinical Transplantation</i> , 2021, 35, e14293.	0.8	4
231	Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. <i>American Journal of Transplantation</i> , 2021, 21, 3811.	2.6	4
232	Corticosteroid withdrawal in solid organ transplantation. <i>Transplantation Reviews</i> , 1998, 12, 140-147.	1.2	3
233	Steroid-sparing regimens in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2001, 6, 313-319.	0.8	3
234	A novel model of allograft rejection: immune reconstitution of Rag-1 recipients with 2C transgenic T-cell receptor lymphocytes. <i>Transplant International</i> , 2005, 18, 101-110.	0.8	3

#	ARTICLE	IF	CITATIONS
235	Pathophysiology of Experimental Autoimmune Encephalomyelitis. , 2016, , 249-280.		3
236	Human class I major histocompatibility complex alleles determine central nervous system injury versus repair. Journal of Neuroinflammation, 2016, 13, 293.	3.1	3
237	Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology. Transplantation Direct, 2018, 4, e392.	0.8	3
238	Clinical outcomes after ABO-incompatible renal transplantation. Lancet, The, 2019, 394, 1988-1989.	6.3	3
239	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation, 2021, 105, 436-442.	0.5	3
240	Kidney Histology, Kidney Function, and Age. American Journal of Kidney Diseases, 2021, 77, 312-314.	2.1	3
241	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2021, 32, 517-518.	3.0	3
242	Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 414-422.	2.2	3
243	Should We Be Performing Pancreas Transplants?. American Journal of Transplantation, 2004, 4, 1935-1936.	2.6	2
244	Antibody-Mediated Injury in the Renal Allograft. , 2012, 17, 219-224.		2
245	Computational Biology: Modeling Chronic Renal Allograft Injury. Frontiers in Immunology, 2015, 6, 385.	2.2	2
246	Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials. American Journal of Transplantation, 2019, 19, 2274-2283.	2.6	2
247	Mesangial expansion at 5 years predicts death and death-censored graft loss after renal transplantation. Clinical Transplantation, 2021, 35, e14147.	0.8	2
248	Chronic graft-versus-host disease in pancreas after kidney transplant recipients â€“ An unrecognized entity. American Journal of Transplantation, 2021, 21, 883-888.	2.6	2
249	Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. American Journal of Transplantation, 2021, , .	2.6	2
250	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	3.2	2
251	Should We Be Performing More Pancreas Transplants?. Clinical Transplants, 2015, 31, 173-180.	0.2	2
252	Clinical and Kidney Structural Characteristics of Living Kidney Donors With Nephrolithiasis and Their Long-term Outcomes. Transplantation Direct, 2022, 8, e1278.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Complications After Hand-Assisted Laparoscopic Living Donor Nephrectomy. Mayo Clinic Proceedings, 2022, 97, 894-904.	1.4	2
254	Donor Scoring System for Cadaveric Renal Transplantation. American Journal of Transplantation, 2001, 1, 162.	2.6	1
255	Chronic Histologic Changes Are Present Regardless of HLA Mismatches. Transplantation, 2020, Publish Ahead of Print, e244-e256.	0.5	1
256	Mesangial matrix expansion in a novel mouse model of diabetic kidney disease associated with the metabolic syndrome. Journal of Nephropathology, 2021, 10, e17-e17.	0.1	1
257	Endoscopic Ultrasound-Guided Dual Ultrasound Hepatic Cyst Aspiration and Sclerotherapy to Ameliorate Portal Hypertension. American Journal of Gastroenterology, 2022, 117, 715-716.	0.2	1
258	Kidney glomerular filtration rate plasticity after transplantation. CKJ: Clinical Kidney Journal, 2022, 15, 841-844.	1.4	1
259	PRELIMINARY EXPERIENCE WITH A CUFFED ePTFE GRAFT FOR HEMODIALYSIS VASCULAR ACCESS. ASAIO Journal, 2000, 46, 216.	0.9	0
260	Tolerance for immunosuppression in organ transplantation. Liver Transplantation, 2004, 10, 573-575.	1.3	0
261	Blood Pressure and Renal Function after Kidney Donation from Hypertensive Living Donors. Transplantation, 2005, 79, 1769-1770.	0.5	0
262	Overcoming antibody barriers to transplantation: ABO-incompatible and positive cross-match kidney transplantation at Mayo Clinic Rochester. International Congress Series, 2006, 1292, 113-119.	0.2	0
263	Evidence that alloantibody is a major risk factor for graft loss and death in living-donor liver transplantation. Surgery, 2010, 147, 845-846.	1.0	0
264	An Important Debate. American Journal of Transplantation, 2011, 11, 1758-1758.	2.6	0
265	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2019, , 355-366.		0
266	Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Current Transplantation Reports, 2021, 8, 272-280.	0.9	0
267	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. Blood, 2007, 110, 4778-4778.	0.6	0
268	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. Blood, 2007, 110, 4779-4779.	0.6	0
269	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2008, , 350-360.		0
270	Transplantation in the Sensitized Recipient and Across ABO Blood Groups. , 2014, , 360-371.		0

#	ARTICLE	IF	CITATIONS
271	Reply to Letter to the Editor. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2017, 39, 347-348.	0.4	0
272	Progressive decline of function in renal allografts with normal one year biopsies: Gene expression studies fail to identify a classifier. Clinical Transplantation, 2021, , e14456.	0.8	0
273	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation, 2021, 105, 1615-1624.	0.5	0
274	P.157: NK and B Cell Subset Assessment in Type I Diabetes Patients on Waitlist for Pancreas Transplantation. Transplantation, 2021, 105, S65-S65.	0.5	0
275	P.138: Patients Report Improved Diabetes Distress After Successful Pancreas Transplantation. Transplantation, 2021, 105, S56-S56.	0.5	0
276	P.155: Altered T Cell Compartment in Type 1 Diabetes With End Stage Renal Disease. Transplantation, 2021, 105, S63-S64.	0.5	0
277	P.140: Impact of Successful Pancreas Transplantation on Patient Reported Hypoglycemia Outcomes. Transplantation, 2021, 105, S57-S57.	0.5	0